Form 4 for CELU Celularity Inc
Accepted 2023-07-19 00:00:00 ET · period of report 2023-07-14 · accession 0000950170-23-033475 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-19 | 2023-07-14 | CELU | Kilcoyne Adrian | Chief Medical Off | A - Grant | $0.00 | +875.0K | 1.18M | +292% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-07-14 | A | A | 875,000 | $0.00 | 1,175,000 | D | — | — | (F1) These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs are subject to (i) time-based vesting over a three-year period, with 25% vesting on the one-year anniversary of the grant date, 25% vesting on the two-year anniversary of the grant date, and the remainder vesting on the three-year anniversary of the grant date, and (ii) performance-based vesting based on the Issuer's stock price, and in each case subject to the Reporting Person's continuous service on each vesting date. (F2) Reflects shares underlying RSUs subject to vesting. |